MOTS-c Pharmacokinetics (ADME): Absorption, Distribution, Metabolism, and Elimination
HealthRX.com
No human pharmacokinetic data exist for MOTS-c
Key numbers
- 5 mgProposed injection strength nominated to FDA, not a dose tested in peopleSource: fda.gov, as cited Nov 8, 2026
- 0.5 to 15 mg/kgMouse dose range in animal studies, which FDA says cannot be converted to a human doseSource: fda.gov, as cited Nov 8, 2026
- 20%Lower body weight in mice on a high-fat diet after 8 weeks of injected MOTS-cSource: fda.gov, as cited Nov 8, 2026
- 912 to 970 daysMedian lifespan in mice given a late-life MOTS-c scheduleSource: fda.gov, as cited Nov 8, 2026
See the public record for MOTS-c
At a glance
- Human pharmacokinetics / none found in the FDA review [1]
- Animal pharmacokinetics / none in living animals [1]
- Only kinetic finding / rapid breakdown in human blood in vitro [1]
- Approved dose / none [1]
- Proposed doses / 5 mg and 10 mg subcutaneous injections [1]
- Peptide size / 16 amino acids, about 2174.6 g/mol [1]
- FDA status / not an approved drug [1]
- Sport / prohibited at all times by WADA [2]
What is the only kinetic finding?
The one kinetic observation FDA cites is an in-vitro experiment in which MOTS-c was quickly broken down in human blood; the agency noted that this raises the question of whether injecting the peptide can produce active levels in people [1]. It is a laboratory result about peptide stability in blood, not a measurement of peptide levels after an injection.
The molecule is a 16-amino-acid peptide (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) of about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 by Lee and colleagues in Cell Metabolism [1][3].
Can a Tmax, Cmax or half-life be quoted?
No measured Tmax, Cmax, half-life, bioavailability or volume of distribution has been reported. The products nominated to FDA were 5 mg and 10 mg subcutaneous injections; these were proposed strengths, not doses tested in people [1]. Mouse experiments used 0.5 to 15 mg/kg, and FDA states those doses cannot be converted into human doses [1].
Questions worth asking
What did the animal work actually measure?
In mice, injected MOTS-c reduced weight gain on a high-fat diet, with about 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneal [1]. A late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [1]. Lee and colleagues reported that treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle as the apparent main target organ and AMPK activation [3]. FDA notes that the molecular targets are unknown and that dose-response relationships were not assessed [1].
Does exercise raising your own MOTS-c say anything about injections?
In a randomized trial of 30 healthy adults assigned to endurance exercise (n=10, 45 minutes of cycling at 70% of estimated VO2max), resistance exercise (n=10) or control (n=10), humanin rose significantly after endurance exercise, MOTS-c showed only a trend to increase, and plasma MOTS-c was not related to fitness [5]. Exercise has also been shown to induce endogenous MOTS-c expression in human skeletal muscle and in the circulation, in people who were not given MOTS-c [4]. Both studies measured the body's own peptide.
What do regulators say about the injected product?
MOTS-c is not an FDA-approved drug and is not a component of one, and FDA found no pharmacopoeial monograph for it and no product authorised by the European Medicines Agency [1]. For injectable peptides the agency's stated concern is immunogenicity from aggregation and peptide-related impurities, and no immunogenicity data exist for MOTS-c [1][6]. FDA's adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports, and the agency found no animal toxicity studies [1]. WADA names MOTS-c in S4.4.1 among AMPK activators, prohibited at all times in and out of competition [2]. An HHS draft policy from October 2026 on certain compounded peptides names MOTS-c acetate for injection; the notice states it is not binding, and it is not an approval or a listing [7][8].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Does the human blood experiment predict what an injection does?
What doses of MOTS-c have been proposed for people?
Do the mouse doses convert to a human dose?
Does exercise raising my own MOTS-c mean an injection behaves the same way?
Is MOTS-c approved anywhere?
Is MOTS-c banned in sport?
References
Show all 10 referencesHide references
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Official web page.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.